Analysts expect Fennec Pharmaceuticals Inc. to report revenue of 17.18 M for Q2 26, against a range of 16.33 M to 18.03 M. The most recent reported quarter, Q1 26, came in at 15.10 M, a 15.6% beat against the 13.06 M consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 7.30 M | 6.97 M | 7.92 M | 8.75 M | 9.65 M | 12.46 M | 13.78 M | 15.10 M | - | - | - | - |
| High Estimate | 12.49 M | 10.14 M | 8.50 M | 8.90 M | 9.58 M | 12.83 M | 16.53 M | 13.47 M | 18.03 M | 18.80 M | 22.41 M | 24.61 M |
| Low Estimate | 10.70 M | 8.40 M | 7.96 M | 7.94 M | 8.32 M | 11.02 M | 14.18 M | 12.66 M | 16.33 M | 17.10 M | 21.01 M | 21.84 M |
| Consensus Estimate | 11.59 M | 9.27 M | 8.23 M | 8.42 M | 8.95 M | 11.92 M | 15.35 M | 13.06 M | 17.18 M | 17.95 M | 21.71 M | 23.23 M |
Analysts expect Fennec Pharmaceuticals Inc. to report earnings per share of 0.02 for Q2 26, against a range of 0.02 to 0.02. The most recent reported quarter, Q1 26, came in at 0.01, a 125.0% beat against the -0.04 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.20 | -0.21 | -0.06 | -0.04 | -0.11 | -0.02 | -0.17 | 0.01 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -0.03 | -0.08 | -0.11 | -0.08 | -0.03 | -0.02 | 0.04 | -0.04 | 0.02 | 0.08 | 0.15 | 0.13 | 0.16 | 0.23 | 0.28 | 0.39 | |||||||||||
| Low Estimate | -0.03 | -0.10 | -0.13 | -0.10 | -0.03 | -0.02 | 0.04 | -0.04 | 0.02 | 0.08 | 0.13 | 0.11 | 0.14 | 0.19 | 0.26 | 0.33 | |||||||||||
| Consensus Estimate | -0.03 | -0.09 | -0.12 | -0.09 | -0.03 | -0.02 | 0.04 | -0.04 | 0.02 | 0.08 | 0.14 | 0.12 | 0.15 | 0.21 | 0.27 | 0.36 |